MRM - MEDIROM Healthcare Technologies reports prelim FY22 results

• MEDIROM Healthcare Technologies ( NASDAQ: MRM ) announced preliminary total revenue for FY22 is expected to be ~¥6.5B ($49.3M), representing a projected increase of ¥1.1B ($8.3M) from FY21.
• The increase was primarily due to the full-year revenue contribution of two subsidiaries, SAWAN and ZACC, which were acquired during 2021, an increase in the revenue from sales of our directly-owned salons to investors, which sales were commenced in the fourth quarter of 2021, and an increase in sales at the directly-operated salons as a result of the recovery from COVID-19 in 2022.
• FY22 operating expenses are expected to be ~¥6.26B ($47.5 M), representing a projected increase of ¥380M ($2.9M) from FY21.
• Operating income for the year is expected to be ~¥240M ($1.8M), representing a projected increase of ¥711M ($5.4M) from FY21.

For further details see: